Готові списки джерел за темами / Dual Anti-Platelet Therapy

Добірка наукової літератури з теми "Dual Anti-Platelet Therapy"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Dual Anti-Platelet Therapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Dual Anti-Platelet Therapy"

1

Webster, Tyler D., Prashant Vaishnava, and Kim A. Eagle. "Perioperative management of dual anti-platelet therapy." Hospital Practice 44, no. 5 (October 19, 2016): 237–41. http://dx.doi.org/10.1080/21548331.2016.1260997.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Segal, Jonathan, and Guven Kaya. "Dual Anti-Platelet Therapy and Gastrointestinal Protection Audit." American Journal of Gastroenterology 107 (October 2012): S116. http://dx.doi.org/10.14309/00000434-201210001-00269.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Cutlip, Donald E. "Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy." US Cardiology Review 11, no. 1 (2017): 31. http://dx.doi.org/10.15420/usc.2017:7:2.

Повний текст джерела
Анотація:
There is controversy regarding the appropriate duration of dual anti-platelet therapy after coronary stenting. Recent guidance has been updated to reflect improved outcomes after second-generation drug-eluting stenting, but a standard duration for all patients is not rational given the different risks for ischemic and bleeding complications. This paper reviews the data for short- and long-term dual anti-platelet therapy and considers approaches for developing a personalized strategy.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Abuzaid, Ahmed, Pragya Ranjan, Carly Fabrizio, Kevin Felpel, Raveen Chawla, Adrienne Topic, and Islam Y. Elgendy. "Single Anti-Platelet Therapy versus Dual Anti-Platelet Therapy after Transcatheter Aortic Valve Replacement: A Meta-Analysis." Structural Heart 2, no. 5 (August 1, 2018): 408–18. http://dx.doi.org/10.1080/24748706.2018.1491082.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Diener, Hans-Christoph. "Update on clopidogrel and dual anti-platelet therapy: neurology." European Heart Journal Supplements 8, suppl_G (October 1, 2006): G15—G19. http://dx.doi.org/10.1093/eurheartj/sul049.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Mărginean, Alina, Claudia Bănescu, Alina Scridon, and Minodora Dobreanu. "Anti-platelet Therapy Resistance – Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities." Journal of Critical Care Medicine 2, no. 1 (January 1, 2016): 6–15. http://dx.doi.org/10.1515/jccm-2015-0021.

Повний текст джерела
Анотація:
AbstractIt is well known that critically ill patients require special attention and additional consideration during their treatment and management. The multiple systems and organ dysfunctions, typical of the critical patient, often results in different patterns of enteral absorption in these patients. Anti-platelet drugs are the cornerstone in treating patients with coronary and cerebrovascular disease. Dual anti-platelet therapy with aspirin and clopidogrel is the treatment of choice in patients undergoing elective percutaneous coronary interventions and is still widely used in patients with acute coronary syndromes. However, despite the use of dual anti-platelet therapy, some patients continue to experience cardiovascular ischemic events. Recurrence of ischemic events is partly attributed to the fact that some patients have poor inhibition of platelet reactivity despite treatment. These patients are considered low- or nonresponders to therapy. The underlying mechanisms leading to resistance are not yet fully elucidated and are probably multifactorial, cellular, genetic and clinical factors being implicated. Several methods have been developed to asses platelet function and can be used to identify patients with persistent platelet reactivity, which have an increased risk of thrombosis. In this paper, the concept of anti-platelet therapy resistance, the underlying mechanisms and the methods used to identify patients with low responsiveness to anti-platelet therapy will be highlighted with a focus on aspirin and clopidogrel therapy and addressing especially critically ill patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Warner, Timothy D., Sven Nylander, and Carl Whatling. "Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy." British Journal of Clinical Pharmacology 72, no. 4 (September 9, 2011): 619–33. http://dx.doi.org/10.1111/j.1365-2125.2011.03943.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Feitosa, Mateus Paiva Marques, Carla David Soffiatti, Jaime Paula Pessoa Linhares Filho, Daniel Valente Batista, Heraldo Guedis Lobo Filho, Eduardo Gomes Lima, and Carlos Vicente Serrano Júnior. "Dual platelet antiaggregation therapy after myocardial revascularization surgery." Revista da Associação Médica Brasileira 65, no. 3 (March 2019): 316–18. http://dx.doi.org/10.1590/1806-9282.65.3.316.

Повний текст джерела
Анотація:
SUMMARY Coronary artery bypass graft (CABG) is a consolidated treatment in patients with coronary artery disease (CAD) for both symptom control and improvement of prognosis. The patency of venous grafts is still the most vulnerable point of the surgical treatment since it presents a high prevalence of occlusion both in the immediate postoperative period and in the long-term follow-up. Aspirin plays a well-established role in this setting, and for a long time, clopidogrel use has been restricted to patients allergic to aspirin. Recently, subgroup analyses of studies with different anti-platelet therapies have shown reduced mortality and cardiovascular events in patients on dual anti-platelet antiplatelet therapy (DAPT) undergoing CABG, although such studies have not been designed to evaluate this patient profile. However, there is still an insufficient number of randomized studies using DAPT in this context, resulting in a disagreement between the European and American cardiology societies guidelines regarding their indication and generating doubts in clinical practice.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Henriksen, P. A., K. Palmer, and N. A. Boon. "Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy." QJM 101, no. 4 (February 12, 2008): 261–67. http://dx.doi.org/10.1093/qjmed/hcm148.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Lee, Dong Hyun, Moo Hyun Kim, Long Zhe Guo, Cai De Jin, Young Rak Cho, Kyungil Park, Jong Sung Park, Tae-Ho Park, and Victor Serebruany. "Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy." International Journal of Cardiology 203 (January 2016): 877–81. http://dx.doi.org/10.1016/j.ijcard.2015.11.068.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Dual Anti-Platelet Therapy"

1

Bevilacqua, William, and Christopher L. Skelly. "In Patients Who Have Undergone a Lower Extremity Bypass for PAD, Does Dual Anti-platelet Therapy Improve Outcomes?" In Difficult Decisions in Surgery: An Evidence-Based Approach, 491–500. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-33293-2_41.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Dual Anti-Platelet Therapy" для конкретних типів джерел:
Статті в журналах
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії